These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

800 related articles for article (PubMed ID: 34872596)

  • 21. Impact of white matter lesions and cognitive deficits on conversion from mild cognitive impairment to Alzheimer's disease.
    Defrancesco M; Marksteiner J; Deisenhammer E; Kemmler G; Djurdjevic T; Schocke M
    J Alzheimers Dis; 2013; 34(3):665-72. PubMed ID: 23254639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
    Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K
    Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accuracy and Psychometric Properties of the Brazilian Version of the Montreal Cognitive Assessment as a Brief Screening Tool for Mild Cognitive Impairment and Alzheimer's Disease in the Initial Stages in the Elderly.
    Pinto TCC; Machado L; Costa MLG; Santos MSP; Bulgacov TM; Rolim APP; Silva GA; Rodrigues-Júnior AL; Sougey EB; Ximenes RCC
    Dement Geriatr Cogn Disord; 2019; 47(4-6):366-374. PubMed ID: 31466064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting conversion from mild cognitive impairment to Alzheimer's disease using brain
    Mitolo M; Stanzani-Maserati M; Capellari S; Testa C; Rucci P; Poda R; Oppi F; Gallassi R; Sambati L; Rizzo G; Parchi P; Evangelisti S; Talozzi L; Tonon C; Lodi R; Liguori R
    Neuroimage Clin; 2019; 23():101843. PubMed ID: 31071594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is the Montreal Cognitive Assessment (MoCA) screening superior to the Mini-Mental State Examination (MMSE) in the detection of mild cognitive impairment (MCI) and Alzheimer's Disease (AD) in the elderly?
    Pinto TCC; Machado L; Bulgacov TM; Rodrigues-Júnior AL; Costa MLG; Ximenes RCC; Sougey EB
    Int Psychogeriatr; 2019 Apr; 31(4):491-504. PubMed ID: 30426911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative study on the validations of three cognitive screening tests in identifying subtle cognitive decline.
    Pan FF; Huang L; Chen KL; Zhao QH; Guo QH
    BMC Neurol; 2020 Mar; 20(1):78. PubMed ID: 32138678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging.
    Roalf DR; Moberg PJ; Xie SX; Wolk DA; Moelter ST; Arnold SE
    Alzheimers Dement; 2013 Sep; 9(5):529-37. PubMed ID: 23260866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tracking Cognitive Decline in Amnestic Mild Cognitive Impairment and Early-Stage Alzheimer Dementia: Mini-Mental State Examination versus Neuropsychological Battery.
    Kim J; Na HK; Byun J; Shin J; Kim S; Lee BH; Na DL
    Dement Geriatr Cogn Disord; 2017; 44(1-2):105-117. PubMed ID: 28768247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association Between Neuropsychiatric Symptom Trajectory and Conversion to Alzheimer Disease.
    Lo TWB; Karameh WK; Barfett JJ; Fornazzari LR; Munoz DG; Schweizer TA; Fischer CE;
    Alzheimer Dis Assoc Disord; 2020; 34(2):141-147. PubMed ID: 31633557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of cognitive decline in Alzheimer's disease and mild cognitive impairment using the CAMCOG: a five-year follow-up.
    Conde-Sala JL; Garre-Olmo J; Vilalta-Franch J; Llinàs-Reglà J; Turró-Garriga O; Lozano-Gallego M; Hernández-Ferrándiz M; Pericot-Nierga I; López-Pousa S
    Int Psychogeriatr; 2012 Jun; 24(6):948-58. PubMed ID: 22278151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anosognosia Is an Independent Predictor of Conversion From Mild Cognitive Impairment to Alzheimer's Disease and Is Associated With Reduced Brain Metabolism.
    Gerretsen P; Chung JK; Shah P; Plitman E; Iwata Y; Caravaggio F; Nakajima S; Pollock BG; Graff-Guerrero A;
    J Clin Psychiatry; 2017; 78(9):e1187-e1196. PubMed ID: 29022655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of the Hungarian Test Your Memory (TYM-HUN), MMSE, and ADAS-Cog tests for patients with mild cognitive impairment (MCI) in a Hungarian population: a cross-sectional study.
    Garbóczy S; Magócs É; Szőllősi GJ; Harsányi S; Égerházi A; Kolozsvári LR
    BMC Psychiatry; 2020 Dec; 20(1):571. PubMed ID: 33256672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mini-Mental State Examination and Montreal Cognitive Assessment as Tools for Following Cognitive Changes in Alzheimer's Disease Neuroimaging Initiative Participants.
    Wang G; Estrella A; Hakim O; Milazzo P; Patel S; Pintagro C; Li D; Zhao R; Vance DE; Li W;
    J Alzheimers Dis; 2022; 90(1):263-270. PubMed ID: 36093696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ecological assessment of mild cognitive impairment and Alzheimer disease using the Rivermead Behavioural Memory Test.
    Bolló-Gasol S; Piñol-Ripoll G; Cejudo-Bolivar JC; Llorente-Vizcaino A; Peraita-Adrados H
    Neurologia; 2014; 29(6):339-45. PubMed ID: 24139389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clock Drawing Test: A Simple Scoring System for the Accurate Screening of Cognitive Impairment in Patients with Mild Cognitive Impairment and Dementia.
    Rakusa M; Jensterle J; Mlakar J
    Dement Geriatr Cogn Disord; 2018; 45(5-6):326-334. PubMed ID: 30036864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations.
    Eikelboom WS; van den Berg E; Singleton EH; Baart SJ; Coesmans M; Leeuwis AE; Teunissen CE; van Berckel BNM; Pijnenburg YAL; Scheltens P; van der Flier WM; Ossenkoppele R; Papma JM
    Neurology; 2021 Sep; 97(13):e1276-e1287. PubMed ID: 34413181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mini Mental State Examination and Logical Memory scores for entry into Alzheimer's disease trials.
    Chapman KR; Bing-Canar H; Alosco ML; Steinberg EG; Martin B; Chaisson C; Kowall N; Tripodis Y; Stern RA
    Alzheimers Res Ther; 2016 Feb; 8():9. PubMed ID: 26899835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia.
    Arbizu J; Prieto E; Martínez-Lage P; Martí-Climent JM; García-Granero M; Lamet I; Pastor P; Riverol M; Gómez-Isla MT; Peñuelas I; Richter JA; Weiner MW;
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1394-405. PubMed ID: 23715905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and demographic predictors of mild cognitive impairment for converting to Alzheimer's disease and reverting to normal cognition.
    Tokuchi R; Hishikawa N; Kurata T; Sato K; Kono S; Yamashita T; Deguchi K; Abe K
    J Neurol Sci; 2014 Nov; 346(1-2):288-92. PubMed ID: 25248955
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.